Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is therefore a need to develop novel ASMs. Brivaracetam (BRV) is an ASM that was developed in a major drug discovery program aimed at identifying selective, high-affinity synaptic vesicle protein 2A (SV2A) ligands, the target molecule of levetiracetam. BRV binds to SV2A with 15- to 30-fold higher affinity and greater selectivity than levetiracetam. BRV has broad-spectrum antiseizure activity in animal models of epilepsy, a favorable pharmacokinetic profile, few clinically relevant drug-drug interactions, and rapid brain penetration. BRV is available in oral and intravenous formulations and can be initiated at target dose without titration. Efficacy and safety of adjunctive BRV (50–200 mg/day) treatment of focal-onset seizures was demonstrated in three pivotal phase III trials (NCT00490035/NCT00464269/NCT01261325), including in patients who had previously failed levetiracetam. Efficacy and safety of adjunctive BRV were also demonstrated in adult Asian patients with focal-onset seizures (NCT03083665). In several open-label trials (NCT00150800/NCT00175916/NCT01339559), long-term safety and tolerability of adjunctive BRV was established, with efficacy maintained for up to 14 years, with high retention rates. Evidence from daily clinical practice highlights BRV effectiveness and tolerability in specific epilepsy patient populations with high unmet needs: the elderly (≥ 65 years of age), children (< 16 years of age), patients with cognitive impairment, patients with psychiatric comorbid conditions, and patients with acquired epilepsy of specific etiologies (post-stroke epilepsy/brain tumor related epilepsy/traumatic brain injury-related epilepsy). Here, we review the preclinical profile and clinical benefits of BRV from pivotal trials and recently published evidence from daily clinical practice. One in three people with epilepsy continue to have seizures despite treatment. Brivaracetam is a medicine used to treat seizures in people with epilepsy. It binds to a protein in the brain (synaptic vesicle protein 2A) and is effective in many different animal models of epilepsy. Brivaracetam enters the brain quickly. It has few interactions with other medicines, which is important because people with epilepsy may be taking additional medicines for epilepsy or other conditions. Brivaracetam is available as tablets, oral solution, and solution for intravenous injection, can be started at the recommended target dose, and is easy to use. In three phase III trials, people with uncontrolled focal-onset seizures taking brivaracetam 50–200 mg each day had fewer seizures than people taking a placebo. Brivaracetam was tolerated well. It also worked well in many people who had previously not responded to antiseizure medications. The efficacy of brivaracetam treatment is maintained for up to 14 years. Brivaracetam treatment reduces seizures in the elderly (≥ 65 years old), in children (< 16 years old), in people with cognitive or learning disabilities, in people with additional psychiatric conditions, and in people with different causes of epilepsy (post-stroke epilepsy, brain-tumor related epilepsy, and traumatic brain injury-related epilepsy). Here, we review brivaracetam characteristics and the results when people with epilepsy received brivaracetam in key clinical trials and real-world studies in daily clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Mechanism of action of clinically approved ASMs. Drugs marked with asterisks indicate that these compounds act by multiple mechanisms (not all mechanisms shown here). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, GABA gamma-aminobutyric acid, GABA-T GABA aminotransferase, GAT GABA transporter, KCNQ a family of voltage-gated potassium channels (also known as the Kv7 family), NMDA N-methyl-D-aspartate, SV2A synaptic vesicle protein 2A. Reproduced with small modifications from Fig. 1 of Löscher et al. [69], licensed under CC BY-NC 4.0](https://figures.cochat.ai/paper-figures/0db1f8af6a8f49dbbb710a7b9a9a85b2/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-1.jpg)
![Fig. 2 Overview of drug discovery efforts at UCB based on modulation of the pyrrolidone-acetamide scaffold (a), properties of BRV and LEV (b), and proposed mechanism of action of BRV and LEV (C). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, BRV brivaracetam, GABA gamma-aminobutyric acid, GAD 65 glutamate decarboxylase 65, HVA high-voltage-activated, IC50 inhibitory half maximal concentration, Ki equilibrium constant, LEV levetiracetam, MES maximal electroshock seizure test, PTZ subcutaneous pentylenetetrazole seizure test, SV2A synaptic vesicle protein 2A. a Reproduced from Fig. 1 of Klitgaard et al. [7], licensed under CC BY-NC-ND 4.0. b Reproduced from Table 31.2 of D’Souza et al. [70], with permission from John Wiley & Sons, Ltd. Panel C: Reproduced with small modifications from Fig. 1 of Feyissa [71], licensed under CC BY-NC 4.0](https://figures.cochat.ai/paper-figures/5e65eec14707466aba085701274dd476/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-2.jpg)
![Fig. 3 Overview of BRV metabolism. BRV brivaracetam, CYP cytochrome P450. Reproduced from Fig. 1 of Moseley et al. [17], licensed under CC BY-NC-ND 4.0](https://figures.cochat.ai/paper-figures/8ed5a0bc85cc4c0f8e33930a36b47349/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-3.jpg)
![Fig. 4 Median percent reduction in POS frequency from baseline (a) and ≥ 50% responder rates (b). BRV brivaracetam, POS partial-onset seizure (focal-onset seizure). Reproduced from Fig.3a and 2B of Ben-Menachem et al. [31], licensed under CC BY-NC-ND 4.0](https://figures.cochat.ai/paper-figures/cdfa8ce96ee042afb641e245c6f9bccd/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-4.jpg)
![Fig. 5 Greater than 50% responder rates in patients treated with BRV, with or without previous LEV exposure (a), percent reduction over PBO in 28-day adjusted POS frequency during the treatment period according to reason for previous discontinuation of LEV (b), and ≥ 50% responder rates for POS frequency from baseline to the end of treatment period according to reason for previous discontinuation of LEV (c). p values are derived from a logistic regression model with effects for treatment, study, and log-transformed baseline focal seizure frequency as a continuous covariate. All p values are exploratory. BRV brivaracetam, LEV levetiracetam, PBO placebo, POS partial-onset seizure (focal-onset seizure). Panel A: Reproduced from Fig. 1A of Asadi-Pooya et al. [32], licensed under CC BY-NC-ND 4.0. Panel B and C: Reproduced from Fig. 4C and D of Klein et al. [30], licensed under CC BY-NC-ND 4.0](https://figures.cochat.ai/paper-figures/4259439783d44f82b21a96bc454da00b/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-5.jpg)
![Fig. 6 Time to PPR elimination in patients with photosensitive epilepsy (a) and proportion of patients with PPR elimination on EEG at designated timepoints (b). Part 1: IV infusion over 15 min (n = 8); part 2: IV infusion over 15 min (n = 8); parts 1 and 2 combined (n = 16). aRange when excluding patient NNN (non-responder in Part 1): 1–5; bPatient OOO completed part 1, but patient PPP participated in part 2. BRV brivaracetam, EEG electroencephalogram, IV intravenous, LEV levetiracetam, PPR photoparoxysmal response. Adapted from Table 1 and 3 of Reed et al. [50], licensed under CC BY-NC 4.0](https://figures.cochat.ai/paper-figures/81a90772b5194077902cf7d11b52cc1f/narrative-review-of-brivaracetam-preclinical-profile-and-clinical-benefits-in-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, both levetiracetam and brivaracetam have favorable safety, simple kinetics, and flexible dosing that support long-term administration [224,225].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [224]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of the burden of active and life-time epilepsy: a meta-analytic approach
Ngugi, A. K., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02481.x · Cited by 1,447 · cited 1×
“Epilepsy is one of the most common and disabling neurological disorders, affecting all age groups and approximately 65 million people globally [1].”
BackgroundLöscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
Psychiatric Comorbidities in People With Epilepsy
Mula, M., Kanner, A. M., Jetté, N., & Sander, J. W. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000874 · Cited by 256 · cited 1×
“The intricate interplay between epilepsy and mental health challenges, such as depression, anxiety, or cognitive impairments, often leads to a complex clinical picture that demands specialized attention [64].”
BackgroundBiton, V., Berkovic, S. F., Abou‐Khalil, B., Sperling, M. R., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12433 · Cited by 253 · cited 3×
“The tolerability and efficacy of adjunctive BRV in adult patients with focal-onset seizures was shown in three phase III, double-blind, randomized, PBO-controlled trials (Clinical-Trials.gov: NCT00490035, NCT00464269, NCT01261325) [28–30].”
BackgroundMethodGillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253 · cited 1×
“BRV has approximately 15-to 30-fold higher affinity to SV2A than LEV and its ability to inhibit vesicle release is superior to LEV [7, 13].”
BackgroundKlein, P., Schiemann, J., Sperling, M. R., Whitesides, J., Liang, W., Stalvey, T., Brandt, C., & Kwan, P. (2015) · Epilepsia · doi:10.1111/epi.13212 · Cited by 239
Self-citationRyvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12432 · Cited by 231 · cited 1×
“Findings from the first two of these trials suggested no additional benefit of BRV in patients taking concomitant LEV [28, 29].”
BackgroundMatagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 224 · cited 3×
“2a) [6–8].”
BackgroundSynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184 · cited 1×
“1 of Löscher et al. [69], licensed under CC BY-NC 4.0 presynaptic calcium channel (Fig.”
BackgroundInfluentialProgress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.09.001 · Cited by 179
Nicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Kwan, P., Trinka, E., Van Paesschen, W., Rektor, I., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12391 · Cited by 164 · cited 1×
“In a phase III, double-blind, randomized, flex-ible-dose, PBO-controlled trial in adult patients with uncontrolled epilepsy (NCT00504881), 49 patients had generalized-onset epilepsy [33].”
BackgroundYates, S. L., Fakhoury, T., Liang, W., Eckhardt, K., Borghs, S., & D'Souza, J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.09.005 · Cited by 155 · cited 1×
“…open-label trial (N01395; NCT01653262) in patients receiving LEV who switched to BRV (50–200 mg/day) because of non-psychotic BAEs, 93.1% of patients had clinically meaningful reductions in BAEs, suggesting that patients who experience BAEs with LEV treatment may benefit from a switch to BRV [65].”
BackgroundInfluentialSargentini‐Maier, M. L., Rolan, P., Connell, J., Tytgat, D., Jacobs, T., Pigeolet, E., Riethuisen, J., & Stockis, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02829.x · Cited by 141 · cited 2×
“BRV exhibits linear and dose-proportional PK across a range of doses which far exceed the therapeutic ones [15–17].”
BackgroundPharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
Sargentini‐Maier, M. L., Espié, P., Coquette, A., & Stockis, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017129 · Cited by 125
Rolan, P., Sargentini‐Maier, M. L., Pigeolet, E., & Stockis, A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03158.x · Cited by 124 · cited 2×
“It has little protein binding ( 20%), and its distribution volume is slightly lower than the total volume of body water [16, 18].”
BackgroundSteinhoff, B. J., Klein, P., Klitgaard, H., Laloyaux, C., Moseley, B. D., Ricchetti-Masterson, K., Rosenow, F., Sirven, J. I., Smith, B., Stern, J. M., et al. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107939 · Cited by 118 · cited 1×
“A systematic review of BAEs (irritability, anger, aggression) in patients with epilepsy reported that switching from LEV to BRV led to improvement in BAEs in 33.3–83.0% of patients [66].”
BackgroundInfluentialSelf-citationEfficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
Ben-Menachem, E., Mameniškienė, R., Quarato, P. P., Klein, P., Gamage, J., Schiemann, J., Johnson, M. E., Whitesides, J., McDonough, B., & Eckhardt, K. (2016) · Neurology · doi:10.1212/wnl.0000000000002864 · Cited by 112 · cited 2×
“The option of starting an ASM at target dose is potentially advantageous for achieving seizure control faster [31].”
BackgroundMethodSelf-citationWood, M. D., & Gillard, M. (2017) · Epilepsia · doi:10.1111/epi.13638 · Cited by 101 · cited 2×
“Evidence from radioligand studies suggests that BRV and LEV act at different binding sites or interact with different conformational states of the SV2A protein [12].”
BackgroundA review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99 · cited 4×
“3) [8].”
BackgroundInfluentialSelf-citationToledo, M., Whitesides, J., Schiemann, J., Johnson, M. E., Eckhardt, K., McDonough, B., Borghs, S., & Kwan, P. (2016) · Epilepsia · doi:10.1111/epi.13416 · Cited by 75 · cited 1×
“Efficacy and tolerability of BRV treatment in adults with focal-onset seizures was also confirmed in a pooled analysis of > 2000 patients receiving BRV 50–200 mg/day during the phase IIb and phase III trials and their associated long-term follow-up trials [40].”
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65
Brivaracetam Disposition in Renal Impairment
Sargentini‐Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T., & Stockis, A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011431457 · Cited by 62 · cited 2×
“No dose adjustment of BRV is needed at any stage of renal dysfunction [24].”
BackgroundA review of the drug−drug interactions of the antiepileptic drug brivaracetam
Moseley, B. D., Chanteux, H., Nicolas, J.-M., Laloyaux, C., Gidal, B. E., & Stockis, A. (2020) · Epilepsy Research · doi:10.1016/j.eplepsyres.2020.106327 · Cited by 62
Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., Maria, G. D., Didato, G., Falcicchio, G., Fanella, M., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00856-3 · Cited by 57 · cited 1×
“A multicenter retrospective study (BRIVA-FIRST) in Italy assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients (≥ 16 years of age; n = 1029) with epilepsy in clinical practice [55].”
MethodStockis, A., Watanabe, S., Rouits, E., Matsuguma, K., & Irie, S. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-14-rg-010 · Cited by 56 · cited 2×
“A phase I, placebo (PBO)-controlled, double-blind, randomized, single (2.5–100 mg) and multiple (2.5–50 mg twice daily) rising oral dose study assessed the adverse event profile and PK of BRV in healthy Japanese men ( n = 80), as well as the impact on PK of the CYP2C19 genotype [22].”
BackgroundResultInfluentialBrivaracetam Disposition in Mild to Severe Hepatic Impairment
Stockis, A., Sargentini‐Maier, M. L., & Horsmans, Y. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.82 · Cited by 49
Schoemaker, R. C., Wade, J. R., & Stockis, A. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.761 · Cited by 48
Gunasekera, C. L., Sirven, J. I., & Feyissa, A. M. (2023) · Journal of Central Nervous System Disease · doi:10.1177/11795735231209209 · Cited by 48 · cited 1×
“The ideal ASM should offer robust control of seizures while minimizing adverse effects [5].”
BackgroundBrivaracetam in the treatment of epilepsy: a review of clinical trial data
Feyissa, A. M. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s143548 · Cited by 43 · cited 1×
“1 of Feyissa [71], licensed under CC BY-NC 4.0 variability in BRV PK was accounted for by differences in concomitant use of enzyme-inducing ASMs and body weight [19, 21].”
BackgroundInfluentialLiu, E., Dilley, D., McDonough, B., Stockis, A., & Daniels, T. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00332-y · Cited by 40
The unmet need for rapid epileptic seizure termination (REST)
Asnis-Alibozek, A. G., & Detyniecki, K. (2020) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2020.100409 · Cited by 40 · cited 1×
“Early control of seizures may reduce the risk of complications and potential harm [44].”
BackgroundBrodie, M. J., Whitesides, J., Schiemann, J., D’Souza, J., & Johnson, M. E. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.08.018 · Cited by 37 · cited 1×
“A post hoc analysis of the pooled phase III trials assessed safety, tolerability, and efficacy of adjunctive BRV (50–200 mg/day) in older patients ≥ 65 years of age ( n = 32) [58].”
MethodKlein, P., Johnson, M. E., Schiemann, J., & Whitesides, J. (2017) · Epilepsia · doi:10.1111/epi.13631 · Cited by 37 · cited 2×
“A post hoc analysis of the pooled phase III trials assessed the time to onset of sustained ≥ 50% responder status in patients randomized to BRV 50–200 mg/day or PBO [34].”
BackgroundMethodSelf-citationO'Brien, T. J., Borghs, S., He, Q. (., Schulz, A., Yates, S. L., & Biton, V. (2020) · Epilepsia · doi:10.1111/epi.16484 · Cited by 36
Wu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35 · cited 2×
“SV2A modulation by both BRV and LEV results in reduced release of neurotransmitter into the synapse, although it is at present unknown how this translates into the antiseizure activity [8, 11, 12].”
BackgroundRoss, J., Stefan, H., Schäuble, B., Day, R. P., & Sander, J. W. A. S. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.06.002 · Cited by 34 · cited 1×
“In a survey of 461 patients with epilepsy from seven European countries, 51% of participants considered a reduced titration period as an important factor in treatment decision making [43].”
BackgroundAsadi‐Pooya, A. A., Sperling, M. R., Chung, S. S., Klein, P., Diaz, A., Elmoufti, S., Schiemann, J., & Whitesides, J. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.02.007 · Cited by 34 · cited 2×
“5a) [32].”
BackgroundSelf-citationToledo, M., Beale, R. C., Evans, J. S., Steeves, S., Elmoufti, S., Townsend, R., Whitesides, J., & Borghs, S. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.10.008 · Cited by 34
Villanueva, V., Laloyaux, C., D'Souza, W. J., Faught, E., Klein, P., Reuber, M., Rosenow, F., Salas‐Puig, J., Insuga, V. M. S., Strzelczyk, A., et al. (2023) · CNS Drugs · doi:10.1007/s40263-023-01033-4 · Cited by 31 · cited 4×
“BRV was effective and well tolerated in a large analysis ( n = 1644) of patient records from multiple independent non-interventional studies of highly drug-resistant epilepsy patients treated with BRV (EXPERIENCE/EPD332) in routine clinical practice [54].”
BackgroundMethodInfluentialSelf-citationNiespodziany, I., Rigo, J., Moonen, G., Matagne, A., Klitgaard, H., & Wolff, C. (2017) · Epilepsia · doi:10.1111/epi.13890 · Cited by 30 · cited 1×
“2b) [14].”
Antiepileptic Drug Titration and Related Health Care Resource Use and Costs
Fishman, J., Kalilani, L., Song, Y., Swallow, E., & Wild, I. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.17337 · Cited by 26 · cited 1×
“Titration of ASMs to first therapeutic dose is common practice for epilepsy treatment but is frequently linked to increased incidences of seizures, an increased rate of hospitalization, and subsequent increase of health cost utilization as compared to the ASM maintenance phase [42].”
ResultLattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Irelli, E. C., Chiesa, V., Dainese, F., Maria, G. D., Didato, G., Falcicchio, G., et al. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00931-4 · Cited by 25 · cited 1×
“A subgroup analysis of the BRIVAFIRST study assessed the effectiveness and tolerability of adjunctive BRV in older patients (≥ 65 years of age) with epilepsy in clinical practice [60].”
MethodParoxysmal Kinesigenic Dyskinesia: Genetics and Pathophysiological Mechanisms
Xu, J., Li, H., & Wu, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01157-z · Cited by 25
Stockis, A., Sargentini‐Maier, M. L., & Brodie, M. J. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.11.001 · Cited by 24
Toledo, M., Brandt, C., Quarato, P. P., Schulz, A., Cleveland, J. M., Wagener, G., & Klein, P. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107897 · Cited by 24 · cited 1×
“In several open-label extension trials (NCT00150800, NCT00175916, NCT01339559) in more than 2000 patients ≥ 16 years of age with a variety of seizure types, the long-term safety and tolerability of adjunctive BRV was established for up to 14 years [37–39].”
BackgroundSelf-citationBrodie, M. J., Fakhoury, T. A., McDonough, B., Colson, A., Stockis, A., Elmoufti, S., & Whitesides, J. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.06.002 · Cited by 22
Ben‐Menachem, E., Baulac, M., Hong, S. B., Cleveland, J. M., Reichel, C., Schulz, A., Wagener, G., & Brandt, C. (2020) · Epilepsy Research · doi:10.1016/j.eplepsyres.2020.106526 · Cited by 21
Szaflarski, J. P., Sadek, A. S., Greve, B., Williams, P., Varner, J., & Moseley, B. D. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107127 · Cited by 20 · cited 1×
“The efficacy of IV BRV in reducing subsequent seizures was similar to IV LZP [51].”
BackgroundLagae, L. G., Klotz, K. A., Fogarasi, A., Floricel, F., Reichel, C., Elshoff, J., Fleyshman, S., & Kang, H. (2023) · Epilepsia · doi:10.1111/epi.17754 · Cited by 20 · cited 2×
“In a phase III, open-label extension trial (NCT01364597), the long-term safety, tolerability, and efficacy of adjunctive BRV was established up to 9.5 years in pediatric patients (aged 1 month to 17 years of age) with epilepsy [62].”
BackgroundInfluentialOtoul, C., Watanabe, S., McCabe, S., & Stockis, A. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.275 · Cited by 18
Szaflarski, J. P., Besson, H., D'Souza, W. J., Faught, E., Klein, P., Reuber, M., Rosenow, F., Salas‐Puig, J., Insuga, V. M. S., Steinhoff, B. J., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12253-z · Cited by 17 · cited 2×
“Additional subgroup analyses from the EXPE-RIENCE study demonstrated that BRV was well tolerated and effective in patients with different etiologies: PSE, brain-tumor related epilepsy (BTRE), and traumatic brain injury-related epilepsy (TBIE) [67].”
BackgroundMethodSelf-citationLattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Irelli, E. C., Chiesa, V., Dainese, F., Maria, G. D., Didato, G., Gennaro, G. D., et al. (2022) · Seizure · doi:10.1016/j.seizure.2022.03.007 · Cited by 16
Inoue, Y., Tiamkao, S., Zhou, D., Cabral‐Lim, L., Lim, K. S., Lim, S. H., Tsai, J.-J., Moseley, B. D., Wang, L., Sun, W., et al. (2024) · Epilepsia Open · doi:10.1002/epi4.12929 · Cited by 16 · cited 1×
“…safety, and tolerability of adjunctive BRV (50 mg/day and 200 mg/day) in adult Asian patients with focal-onset seizures were demonstrated in a phase III, randomized, double-blind, PBO-controlled trial (NCT03083665) and were consistent with BRV trials in predominantly non-Asian populations [36].”
ResultReed, R. C., Rosenfeld, W. E., Lippmann, S. M., Eijkemans, M. J. C., & Trenité, D. G. A. K.-N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00761-1 · Cited by 14
Håkansson, S., Karlander, M., Larsson, D., Mahamud, Z., Ptacek, S. G., Zelezniak, A., & Zelano, J. (2021) · Epilepsia · doi:10.1111/epi.16987 · Cited by 14 · cited 1×
“Personalized ASM selection has the potential to improve outcomes for patients when matching ASM characteristics to patient profile (e.g., age, gender, comorbidities) [4].”
BackgroundOrlandi, N., d’Orsi, G., Pauletto, G., Nilo, A., Sicurella, L., Pescini, F., Giglia, F., Labate, A., Laganà, A., Renna, R., et al. (2023) · Seizure · doi:10.1016/j.seizure.2023.04.015 · Cited by 14 · cited 1×
“In a cohort of 97 patients treated in neurology units, IV BRV was well tolerated for the treatment of seizure clusters, and early administration was associated with a lower risk of evolution into status epilepticus [53].”
BackgroundLee, K., Klein, P., Dongre, P., Choi, E. J., & Rhoney, D. H. (2022) · Journal of Intensive Care Medicine · doi:10.1177/08850666211073598 · Cited by 13 · cited 2×
“In addition, several studies suggest that IV BRV reduces seizures and is well tolerated in patients with status epi-lepticus [52].”
BackgroundSelf-citationNaganawa, M., Gallezot, J., Finnema, S. J., Maguire, R. P., Mercier, J., Nabulsi, N., Kervyn, S., Henry, S. E., Nicolas, J.-M., Huang, Y. H., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00944-5 · Cited by 12
Pharmacotherapeutic considerations for late-onset epilepsy
Brigo, F., & Lattanzi, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1865311 · Cited by 11 · cited 1×
“The intersection of aging and epilepsy brings forth complex medical issues, including cognitive decline, comorbidities, and polypharmacy [57].”
BackgroundTime course of 75%–100% efficacy response of adjunctive brivaracetam
Klein, P., Laloyaux, C., Elmoufti, S., Gasalla, T., & Martin, M. S. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13287 · Cited by 10 · cited 2×
“On day 1, ≥ 75% sustained responder rates were 10.8% and 9.3% for BRV 100 mg/day and 200 mg/day versus 3.1% for PBO and ≥ 90% sustained responder rates were 6.9% and 5.3% for BRV 100 mg/ day and 200 mg/day versus 1.2% for PBO [35].”
BackgroundInfluentialSelf-citationPharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants
Stockis, A., Nicolas, J., Sargentini‐Maier, M. L., & Krauwinkel, W. J. J. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1264 · Cited by 7 · cited 2×
“A phase I, open-label, repeated-dose study assessed the PK, metabolism, safety, and tolerability of BRV in 16 healthy elderly volunteers (65–78 years of age) [23].”
BackgroundBrivaracetam or levetiracetam in status epilepticus?: Lessons from the photosensitivity model
Trenité, D. G. A. K.-N., & Reed, R. C. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.109018 · Cited by 5
D’Souza, J., & Perucca, E. (2015) · doi:10.1002/9781118936979.ch31 · Cited by 3
Research works printed but not linked: 3
- National Institute for Health and Care Excellence. Epilepsies in children, young people and adults 2022. www.nice.org.uk/guidance/ng217. Accessed 27 Feb 2024. 35700282
- Mercier J Holden D Deo AK Brivaracetam achieves brain SV2A occupancy faster than levetiracetam Epilepsy Curr. 2015 15 Suppl 1 343
- Steinhoff BJ Christensen J Doherty CP Cognitive performance and retention after 12-month adjunctive brivaracetam in difficult-to-treat patients with epilepsy in a real-life setting Epilepsia 2021 62 142 143
Cited by
Saghir, K. A., Ashraf, W., Mushtaq, R. M. Z., Alqahtani, F., & Imran, I. (2025) · Behavioural Neurology · doi:10.1155/bn/8037864 · Cited by 7
“Brivaracetam (BRV) targets a di ff erent receptor, the SV2A protein on neurotransmitter-containing synaptic vesicles, which modulates neurotransmitter release with fewer behavioral side e ff ects compared to levetiracetam [9].”
Gou, C., Yang, M., Zhao, Q., & Han, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1740747 · Cited by 3
Meng, Z., Li, X., Liao, Y., Feng, F., & Wang, T. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2460435 · Cited by 2
“The main side effects of the drug (including somnolence, fatigue, and dizziness) are generally mild, and most patients experience a reduction in these symptoms during prolonged use [12,13].”
Recent Advances in the Management of Seizures in Children
Besag, F., Vasey, M. J., & Chin, R. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00710-9 · Cited by 7
“Brivaracetam (BRV), is a racetam derivative closely related to the established ASM levetiracetam, with selective high affinity for the synaptic vesicle protein 2A (SV2A) [84, 85].”
Huang, A., Wan, Y., Song, X., Feng, W., Ju, S., & Wang, Y. (2026) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.5c11399 · Cited by 2
Metadata
- Authors
- Klein, P., & Bourikas, D.
- Affiliations
- Mid Atlantic Epilepsy and Sleep Center (US)
- Corresponding author
- Klein, Pavel
- Venue
- Advances in Therapy
- Published
- 2024-05-29
- Volume
- 41
- Issue
- 7
- Pages
- 2682-2699
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC11213745
- OpenAlex
- W4399118098
- Cited by
- 21
- References
- 65
- Citations by year
- 2026: 7 · 2025: 14
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- UCB Pharma
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- brivaracetam, epilepsy, antiepileptic drugs, SV2A, levetiracetam, focal seizures, adjunctive therapy, drug-resistant epilepsy, pharmacokinetics, drug-drug interactions, long-term tolerability, pediatric epilepsy, elderly patients, cognitive impairment, post-stroke epilepsy, brain tumor-related epilepsy
- MeSH terms
- Adult, Animals, Anticonvulsants, Child, Drug Evaluation, Preclinical, Epilepsy, Humans, Pyrrolidinones, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.